Altimmune (NasdaqGM:ALT) 2026 Conference Transcript

Summary of Altimmune Conference Call Company Overview - Company: Altimmune (NasdaqGM:ALT) - Event: Citizens Life Sciences Conference on March 10, 2026 - Key Speakers: Jerry Durso (CEO), Linda Richardson (Chief Commercial Officer), Greg Weaver (CFO) Core Industry and Product Insights - Lead Product: Pemvidutide, targeting multiple liver indications, primarily MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [4][5] - Phase 2 Trials: - Positive results from 24-week and 48-week readouts, showing significant impact on MASH resolution and good tolerability [6][10] - Weight loss and trends on fibrosis were noted, although the fibrosis endpoint was not met due to a high placebo response [7][14] - Phase 3 Trial Plans: - Anticipated initiation in 2026 with a focus on a 52-week endpoint and a cohort of nearly 1,000 patients [9][18] - Inclusion of a titration scheme to improve tolerability and patient retention [12][26] Mechanism of Action - Dual Mechanism: Pemvidutide combines glucagon and GLP-1 in a 1:1 ratio, aiming to address both liver fat reduction and metabolic effects [28][29] - Differentiation: The one-to-one ratio is believed to enhance tolerability and efficacy compared to other glucagon/GLP-1 combinations [29][41] Market Position and Competitive Landscape - Market Need: High unmet need in the MASH space, with increasing recognition from physicians and payers [56][60] - Competitors: Other GLP-1 therapies and FGF21s are noted, with pemvidutide expected to have a competitive edge due to its unique profile [62][53] - Commercial Strategy: Focus on maintaining tolerability and addressing weight loss, which is critical for MASH patients [38][61] Financial Position - Cash Position: Strong balance sheet with a runway into 2028, having raised approximately $300 million over the past year [78] - Strategic Funding: Open to potential partnerships, especially for ex-US markets [79] Additional Insights - Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ALD): Ongoing studies with anticipated readouts in 2026, highlighting the potential of pemvidutide in these areas [66][67] - Market Research: Indications that current therapies are not meeting weight loss needs, positioning pemvidutide favorably [60][61] Conclusion - Altimmune is poised to advance pemvidutide through its upcoming phase 3 trials, with a strong focus on addressing the significant unmet needs in liver disease management and maintaining a competitive edge in the evolving therapeutic landscape. The company is actively preparing for commercialization while ensuring a robust financial foundation to support its initiatives.